JP
Therapeutic Areas
Heron Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZYNRELEF (bupivacaine/meloxicam) extended-release solution | Post-operative pain (soft tissue and orthopedic surgical procedures) | Approved |
| SUSTOL (granisetron) extended-release injection | Prevention of acute and delayed Chemotherapy-Induced Nausea and Vomiting (CINV) | Approved |
| HTX-034 (bupivacaine/meloxicam/adrenaline) | Post-operative pain | Phase 3 |
| HTX-011 (ZYNRELEF) Pediatric | Pediatric post-operative pain | Phase 3 |
| HTX-019 (aprepitant injectable suspension) | Prevention of CINV | Phase 2 |
Leadership Team at Heron Therapeutics
CA
Craig A. Collard
Chief Executive Officer
DS
David Szekeres
Chief Commercial Officer
WF
William Forbes
Executive Vice President, Chief Development Officer
AM
Adam Morgan
Executive Vice President, General Counsel
KM
Kimberly Manhard
Executive Vice President, Research & Development
ID
Ira Duarte
Chief Financial Officer
BQ
Barry Quart
Founder and Director